Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Chugai Pharmaceutical Co Ltd    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO LTD (4519)
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Financials (JPY)
Sales 2018 558 B
EBIT 2018 112 B
Net income 2018 85 907 M
Finance 2018 199 B
Yield 2018 1,15%
Sales 2019 612 B
EBIT 2019 142 B
Net income 2019 104 B
Finance 2019 217 B
Yield 2019 1,38%
P/E ratio 2018 38,16
P/E ratio 2019 31,06
EV / Sales2018 5,69x
EV / Sales2019 5,15x
Capitalization 3 369 B
More Financials
Company
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of the pharmaceuticals.Its operations are carried out through the following business divisions: Research, Development, Production, Marketing, Medical Affairs and Drug Safety.The... 
More about the company
Surperformance© ratings of Chugai Pharmaceutical Co L
Trading Rating : Investor Rating :
More Ratings
Latest news on CHUGAI PHARMACEUTICAL CO L
06/14CHUGAI PHARMACEUTICAL : HEMLIBRA® Receives Priority Review Status from U.S. FDA ..
AQ
06/06CHUGAI PHARMACEUTICAL : Priority Review for Hemlibra in new hemophilia A indicat..
AQ
06/05CHUGAI PHARMACEUTICAL : HEMLIBRA® Receives Priority Review Status from U.S. FDA ..
BU
05/29CHUGAI PHARMACEUTICAL : Application for Approval of Additional Indication of Cyt..
AQ
05/26CHUGAI PHARMACEUTICAL : seeks Japanese approval for Actemra to treat adult patie..
AQ
05/25CHUGAI PHARMACEUTICAL : Humanized Anti-Human IL-6 Receptor Monoclonal Antibody '..
AQ
05/21CHUGAI PHARMACEUTICAL : Presents Results of Two Pivotal Phase lll Studies for it..
BU
05/21CHUGAI PHARMACEUTICAL : Presents Results of Two Pivotal Phase III Studies for it..
PU
05/17CHUGAI PHARMACEUTICAL : Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nem..
AQ
05/17CHUGAI PHARMACEUTICAL : Anti-IL-31 Receptor A Humanized Monoclonal Antibody 'nem..
AQ
More news
Sector news : Pharmaceuticals - NEC
06/22Federal Judge Gives Lilly Win on Alimta Regimen Patent
DJ
06/22JOHNSON & JOHNSON : Remakes Top Leadership -- Update
DJ
06/22JOHNSON & JOHNSON : Worldwide Chairman Peterson to Retire
DJ
06/22SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/22Roche to Appoint James Sabry as Head of Partnering
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
06/05Chugai’s HEMLIBRA® Receives Priority Review Status from U.S. FDA for Hemophil.. 
06/05Chugai’s HEMLIBRA® Receives Priority Review Status from U.S. FDA for Hemophil.. 
06/01Hypoparathyroidism Pipeline Analysis 2018: 5 Drugs Currently in Different Pha.. 
05/22Chugai’s Alecensa gains wider market in Taiwan with first-line NSCLC nod 
05/21Chugai Presents Results of Two Pivotal Phase lll Studies for its Bispecific A.. 
More tweets
Qtime:19
News from SeekingAlpha
05/31ALEXION PHARMACEUTICALS : Clinical Progress, Acquisitions And The Competition (P.. 
04/27Chugai Pharmaceutical's (CHGCF) Management on Q1 2018 Results - Earnings Call.. 
04/25Chugai Pharmaceutical Co., Ltd. ADR 2018 Q1 - Results - Earnings Call Slides 
04/24Chugai Pharmaceutical reports Q1 results 
03/25WEEK IN REVIEW : James Watson To Lead New Shenzhen Biopharma Research Center 
Chart CHUGAI PHARMACEUTICAL CO L
Duration : Period :
Chugai Pharmaceutical Co L Technical Analysis Chart | 4519 | JP3519400000 | 4-Traders
Technical analysis trends CHUGAI PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 5 867  JPY
Spread / Average Target -2,5%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka President, CEO & Representative Director
Osamu Nagayama Chairman
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Motoo Ueno Vice Chairman, Head-Audit & CSR Promotions
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO LTD4.33%30 624
JOHNSON & JOHNSON-12.27%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-12.58%191 785
MERCK AND COMPANY8.90%165 373